세계 항생물질 내성 시장 : 규모, 점유율, 동향 분석 보고서 -질환별, 병원체별, 약제 클래스별, 작용기전별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

항생제 내성 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 항생제 내성 시장 규모는 2024년부터 2030년까지 복합 연간 성장률(CAGR) 5.27%를 기록할 전망이며, 2030년에는 124억 8,000만 달러에 달할 것으로 예측됩니다.

항생제의 오용과 과도한 사용으로 인한 항생제 내성 감염 증가는 시장 성장의 주요 요인입니다. 또한 세계적으로 환자 수가 증가하고 있으며 질병 치료와 관련된 비용이 높다는 것은 예측 기간 동안 시장 성장을 밀어 올릴 것으로 예상됩니다.

그람 음성 감염의 유행은 우려되는 속도로 증가하고 있습니다. 이러한 감염은 시장에서 이용 가능한 치료 옵션이 적습니다. 언메트 요구가 높기 때문에 새로운 치료법에 대한 수요도 높기 때문에 중소규모의 제약회사는 신규 치료법의 개발에 적극적으로 임하고 있습니다. 또한 정부 및 기타 기관도 혁신적인 치료법 개발을 추진하기 위해 연구 활동을 지원합니다.

여러 중견 생명 공학 기업이 항생제 내성 감염의 표적 치료제로이 분야에 진출하고 있습니다. 다양한 제조업체가 특히 약물 내성 감염을 위해 소수의 사람들을 대상으로 한 치료법을 개발하고 있습니다.

미국 정부는 BARDA와의 제휴로 항생제 내성 질환에 대한 새로운 치료법의 개발을 뒷받침하기 위해 여러 기업을 지원하고 있습니다. BARDA는 GSK, 테트라 페이즈, 바실레아, 아스트라제네카 등 제약 회사와도 제휴하고 있습니다. 많은 국가와 국제기구가 약물 내성 감염의 패턴을 감시 및 연구하기 위한 전문 그룹과 얼라이언스를 결성하고 있습니다.

예를 들어 WHO는 세계 항균제 내성 감시 시스템(Global Antimicrobial Resistance Surveillance System: GLASS)을 도입하여 항생제 내성 감염을 세계 수준에서 모니터링하고 있습니다. 마찬가지로 캐나다 공중 보건국은 국가 수준에서 약물 내성 감염 패턴을 조사하기 위해 캐나다 항균제 내성 감시 시스템(CARSS)을 도입했습니다.

그러나 WHO가 2023년 3월에 발표한 리뷰에 따르면 항생제의 파이프라인 활동은 제한적이며 2017년부터 2021년 사이에 승인된 새로운 항생제는 단 12가지에 불과합니다. 이 리뷰는 또한 개발중인 새로운 후보 약물은 27 유형에 불과하며, 그 중 WHO가 정의하는 항생제 내성을 극복 할 수있을 정도로 "혁신적"이라고 생각되는 것은 6 유형에 불과하다고합니다.

항생제 내성 시장 보고서 하이라이트

• 2023년에는 cUTI가 가장 큰 시장 점유율을 차지하며 앞으로 수년간 시장에서 우위를 유지할 것으로 예상됩니다.
• 제제는 예측 기간 동안 가장 빠른 복합 연간 성장률(CAGR)로 성장할 것으로 예측됩니다.
• 북미는 2023년 항생제 내성 산업을 지배했습니다. 내성 그람 양성 및 음성 감염의 심각한 부담에 대응하기 위해 미국 국가 행동 계획에 의해 설정된 목표 목표가 시장을 견인하는 주요 요인입니다.
• 아시아태평양은 항생제의 과잉소비, 기술의 진보, 항생제 내성 검사,치료,관리에 관한 의식이 높아짐에 따라 예측기간 중 가장 빠른 성장을 보이게 됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항생제 내성 시장 변수, 동향 및 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 항생제 내성 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 항생물질 내성 시장 : 질환의 추정,동향 분석

• 질병 시장 점유율(2023년,2030년)
• 부문 대시보드
• 질병별 세계 항생제 내성 시장 전망
• 이하 시장 규모, 예측 및 동향 분석(2018년-2030년)

제5장 항생물질 내성 시장 : 병원 추정,동향 분석

• 병원체 시장 점유율(2023년,2030년)
• 부문 대시보드
• 병원체별 세계 항생제 내성 시장 전망
• 이하 시장 규모, 예측 및 동향 분석(2018년-2030년)

제6장 항생물질 내성 시장 : 약제 클래스의 추정,동향 분석

• 의약품 클래스 시장 점유율(2023년,2030년)
• 부문 대시보드
• 약제 클래스별 세계 항생제 내성 시장 전망
• 이하 시장 규모, 예측 및 동향 분석(2018년-2030년)

제7장 항생물질 내성 시장 : 작용 추정,동향 분석

• 액션의 메커니즘 시장 점유율(2023년,2030년)
• 부문 대시보드
• 작용기전별 세계 항생제 내성 시장 전망
• 이하 시장 규모, 예측 및 동향 분석(2018년-2030년)

제8장 항생물질 내성 시장 : 유통 채널의 추정,동향 분석

• 유통 채널 시장 점유율(2023년,2030년)
• 부문 대시보드
• 유통 채널별 세계 항생제 내성 시장 전망
• 이하 시장 규모, 예측 및 동향 분석(2018년-2030년)

제9장 항생물질 내성 시장 :지역 추정,동향 분석

• 지역 시장 점유율 분석(2023년,2030년)
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 트렌드 분석(2018년-2030년):
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 회사/경쟁의 분류
• 벤더 상황
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • Melinta Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics
  • ACHAOGEN, INC.
  • Entasis therapeutics
  • AbbVie
  • Merck &Co. Inc.

BJH

영문 목차

영문목차

Antibiotic Resistance Market Growth & Trends:

The global antibiotic resistance market size is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period.

The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.

Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.

The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.

For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.

However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered "innovative" enough to be capable of overcoming antibiotic resistance as defined by WHO.

Antibiotic Resistance Market Report Highlights:

• In 2023, cUTI accounted for the largest market share and is anticipated to maintain its dominance in the global market in the coming years
• Combination drugs are expected to grow at the fastest CAGR over the forecast period
• North America dominated the antibiotic resistance industry in 2023. The target goals set by the U.S. national action plan in response to the significant burden of resistant gram-positive and negative infections is the key factor driving the market
• Asia Pacific is set to witness the fastest growth over the forecast period due to excessive consumption of antibiotics, advancements in technology, and growing awareness about antibiotic resistance testing, treatment, & management of the same.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Pathogen
  • 1.2.3. Drug Class
  • 1.2.4. Mechanism of Action
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary Distribution Channels
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Distribution Channels
• 1.9. List of Primary Distribution Channels
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease
  • 2.2.2. Pathogen
  • 2.2.3. Drug Class
  • 2.2.4. Mechanism of Action
  • 2.2.5. Distribution Channel
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antibiotic Resistance Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing burden of antibiotic-resistant infections
    • 3.2.1.2. Growing need for new antibiotic therapies
    • 3.2.1.3. Rising public health concern and awareness
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of therapeutics
• 3.3. Antibiotic Resistance Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

• 4.1. Disease Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Antibiotic Resistance Market by Disease Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. cUTI (Complicated Urinary Tract Infections)
    • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. CDI (Clostridioides difficile Infection)
    • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. ABSSSI (Acute bacterial skin and skin structure infections)
    • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. HABP (Hospital-acquired bacterial pneumonia)
    • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. CABP (Community-acquired pneumonia)
    • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. cIAI (Complicated intra-abdominal infection)
    • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.7. BSI (Bloodstream infection
    • 4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

• 5.1. Pathogen Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Antibiotic Resistance Market by Pathogen Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. E. coli
    • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. K. pneumoniae
    • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. P. aeruginosa
    • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. S. aureus
    • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. A. baumannii
    • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. S. pneumoniae
    • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.7. H. influenzae
    • 5.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.8. C. difficile
    • 5.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.9. E. faecium
    • 5.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

• 6.1. Drug Class Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Antibiotic Resistance Market by Drug Class Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Oxazolidinones
    • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.4.2. Lipoglycopeptides
    • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Tetracyclines
    • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.4. Combination therapies
    • 6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.5. Cephalosporins
    • 6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

• 7.1. Mechanism of Action Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Antibiotic Resistance Market by Mechanism of Action Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Protein Synthesis Inhibitors
    • 7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 7.4.2. Cell Wall Synthesis Inhibitors
    • 7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. RNA Synthesis Inhibitors
    • 7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 7.4.4. DNA Synthesis Inhibitors
    • 7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Others
    • 7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Antibiotic Resistance Market by Distribution Channel Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Hospital Pharmacies
    • 8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 8.4.2. Retail Pharmacies
    • 8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. Online Pharmacies
    • 8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.2. Mexico
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/reimbursement structure
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Melinta Therapeutics
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Disease benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Basilea Pharmaceutica Ltd.
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Disease benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Tetraphase Pharmaceuticals
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Disease benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Theravance Biopharma
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Disease benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. WOCKHARDT
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Disease benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Paratek Pharmaceuticals, Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Disease benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Seres Therapeutics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Disease benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. ACHAOGEN, INC.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Disease benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Entasis therapeutics
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Disease benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. AbbVie
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Disease benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Merck & Co. Inc.
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Disease benchmarking
    • 10.3.14.4. Strategic initiatives

관련자료